Retatrutide and autoimmune disease: explore how this investigational triple receptor agonist works, what the current evidence shows, UK regulatory status, and what to discuss with your GP or specialist.
BPC-157 and retatrutide together: understand the serious risks, lack of clinical evidence, and UK regulatory status of combining these two unapproved experimental compounds. Read our expert guide.
Retatrutide and autoimmune disease: explore how this investigational triple receptor agonist works, what the current evidence shows, UK regulatory status, and what to discuss with your GP or specialist.
